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Abstract
Background: Liver dominates the production and secretion of apolipoprotein B (apoB) and evidence shows that
liver malfunction induced by hepatitis B virus (HBV) infection could lead to apolipoprotein metabolism disorders.
The present study was undertaken to assess the effects of HBV on apoB expression.
Methods: Clinical examination: serum apoB levels in patients with chronic HBV infection and in healthy individuals
were measured by immunoturbidimetry using biochemical analyzer Olympus 5400. Cell study: mRNA and protein
expression levels of apoB in HepG2 and HepG2.2.15 cells were measured by RT-PCR and Western blot. Alternatively,
HBV infectious clone pHBV1.3 or control plasmid pBlue-ks were tranfected into HepG2 cells, and mRNA and protein
expression levels of apoB, as well as the microsomal triglyceride transfer protein (MTP) in tranfected HepG2 cells
were also measured by RT-PCR and western blot.
Results: Serum apoB level was much lower in chronic HBV patients as compared to healthy individuals (P < 0.05).
Expression of apoB mRNA and protein was lower in HepG2.2.15 cells than in HepG2 cells. Similarly, expression of
apoB mRNA and protein was lower in pHBV1.3 transfected HepG2 cells than in pBlue-ks transfected HepG2 cells.
Expression of MTP mRNA and protein in pHBV1.3 transfected HepG2 cells was reduced in a dose-dependent
fashion.
Conclusion: HBV infection plays an inhibitory effect on apoB expression.
Keywords: hepatitisB virus, chronic HBV infection;lipid metabolism, apolipoprotein B, microsomal triglyceride trans-
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Introduction
Hepatitis B virus (HBV) is a 3.2-kb, hepatotropic DNA
virus that infects about one third of the world’sp o p u l a -
tion (2 billion) at present time. Although acute infection
of HBV in most people can trigger natural immunity to
this virus, patients with persistent infection are prone to
developing chronic hepatitis, liver cirrhosis, and/or
hepatocellular carcinoma (HCC) [1-3]. According to
WHO, an estimated 600,000 people die every year due
to the consequences of HBV infection [4]. It is generally
believed that HBV infection is non-cytopathic, with its
disease pathogenesis mediated by host innate and adap-
tive immune responses, as well as other host-virus inter-
actions [5].
Liver plays an important role in lipid metabolism and is
thought to be the major assembly center for the produc-
tion of most endogenous lipids, apolipoproteins, and lipo-
proteins. Apolipoprotein B-100 (apoB), a major protein
component of very low density lipoprotein (VLDL) and
low density lipoprotein (LDL), is made in the liver and
required for stabilizing lipoprotein structure. ApoB helps
direct transport of triglycerides that is part of the VLDL or
LDL complex and acts as a ligand recognized by the LDL
receptor to exert effects on cholesterol metabolism.
Increased plasma apoB and LDL cholesterol levels are
considered as risk factors for coronary heart disease [6-8].
Another protein factor that is absolutely required for
VLDL assembly and maturation is the microsomal trigly-
ceride-transfer protein (MTP). In the absence of MTP,
apoB- containing lipoprotein syntheses cannot be achieved
properly. Under physiological circumstances, the integrity
of cellular functions of liver ensures lipid metabolism
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induced hepatic cellular dysfuntion and damage can lead
to plasma lipid and lipoprotein disorders. For instance,
hypertriglyceridemia and decreased plasma high density
l i p o p r o t e i n( H D L )a r ef o u n di np a t i e n t ss u f f e r e df r o m
acute hepatitis B, and chronic lipid consumption and
reduced serum lipid levels are often associated with the
persistent HBV infection [11].
It has been demonstrated that HBV infection leads to
changes of apolipoprotein mRNA abundance in cultured
hepatoma cells [12]. The present study was undertaken
to assess the effects of HBV on apoB expression. We
measured and compared the serum apoB levels in
patients with chronic HBV infection and in healthy indi-
viduals, and analyzed the apoB mRNA and protein
expression levels in the presence of HBV at the cellular
level. Our results suggest there is an inverse correlation
between HBV infection and apoB expression.
Materials and methods
Study population
148 chronic hepatitis B patients (CHB) were recruited
from Zhongnan Hospital of Wuhan University in this
study from June 2009 through March 2011. The diagno-
sis of chronic hepatitis B(CHB) was confirmed by the
serological examination of HBsAg for more than 6
months. 116 healthy donors negative for all viral hepati-
tis markers and with normal liver function profile served
as controls. This study was in compliance with the Hel-
sinki Declaration, and all patients gave written informed
consent for participation.
Measurement of apoB serum levels
Measurement of apoB serum levels was determined by
immunoturbidimetry using an automated spectrophot-
ometer (Olympus AU 5400, Olympus Optical Co.,
Japan) and a commercial kit (RANDOX Laboratories
Ltd., United Kingdom).
Cell culture and transfection
HepG2 and HepG2.2.15 human liver cell lines were
obtained from American Type Culture Collection (A.T.C.
C.), Manassas, VA, U.S.A. Both cell lines were maintained
using DMEM (Dulbecco’s modified Eagle’s medium) sup-
plemented with 10% fetal bovine serum at 37 °C in a
humidified 5% CO2 incubator. Transient transfections of
HepG2 cell with pHBV1.3 (a plasmid containing 1.3-fold
HBV genome as described previously) or pBlue-ks were
conducted using Lipofectin2000 (Invitrogen, U.S.A) fol-
lowing the manufacturer’s instruction [13].
Reverse Transcriptase (RT)-PCR analysis
Total RNA from cell samples was prepared using TRIZOL
(Invitrogen, Carlsbad, CA, USA) and then reverse
transcribed with an oligo(dT) primer. The resulting cDNA
was PCR amplified with the gene-specific primers
designed for:
ApoB, 5’-CACAGGCATCAGCCCACTT-3’ (sense)
and 5’-TGCGAGGCCCATCTTCTTA-
3’(antisense);
MTP, 5’-CGTTCGGCATCTACTTACA-3’(sense)
and 5’-GACCACCCTGGACCTCTAT-
3’(antisense);
b-actin. 5’-ATGATATCGCCGCGCTCG-3’ (sense)
and 5’-CGCTCGGTGAGGATCTTCA -3’
(antisense).
The PCR products were detected on 2% agarose gel
electrophoresis and visualized under UV light with ethi-
dium bromide stain.
Western blot analysis
Cell samples were lysed with Nonidet P-40 lysis buffer
(10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2,
and 0.5% Nonidet P-40). The cell lysates were then cen-
trifuged at 3000 × g for 10 min, the supernatants were
used in the assay. Protein samples were separated on
12% SDS-polyacrylamide gel electrophoresis and then
transferred to nitrocellulose membrane. After blocking
non-specific binding sites, western blot was performed,
using specific antibody against apoB (Santa Cruz Bio-
technology Inc., Santa Cruz, CA), specific antibody
against MTP (Sigma), and, as an internal control, a
monoclonal antibody against b-actin (Sigma). After
washing, blots were developed with horseradish peroxi-
dase-labelled goat anti-rabbit IgG, using an Enhanced
Chemiluminescence Kit (Amersham Life Sciences).
Statistical analysis
Statistical analysis was performed with SPSS13.0 software.
Values were expressed as means ± SD. Means were com-
pared by t tests to determine statistical significance. A p
value less than 0.05 (P < 0.05) was considered significant.
Results
Comparison of serum apoB levels between chronic HBV
patients and healthy controls
To investigate the correlation between HBV infection
and apoB expression, we examined the serum apoB
levels in CHB patients compared to HBV-negative
donors. As shown in Figure 1, the serum levels of apoB
was much lower in CHB as compared to healthy indivi-
duals (0.72 ± 0.18 g/L vs 0.84 ± 0.22 g/L).
Effect of HBV on levels of apoB mRNA and protein
Previous studies demonstrated that HBV infection alters
the expression of a wide array of apolipoprotein genes
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HBV on apoB synthesis, the relative expression of apoB
mRNA in HepG2 cells and HepG2.2.15 cells was evalu-
ated by RT-PCR. Cellular RNA was reverse transcribed
and then amplified with primers specific for apoB and
housekeeping gene b-actin. As shown in Figure 2A, the
expression of apoB mRNA in HepG2.2.15 cells was sig-
nificantly lower compared with that in HepG2 cells. In
addition, the b-actin mRNA remained constant between
the two cell lines.
To determine apoB protein expression in HepG2 and
HepG2.2.15 cells, Western blot analysis was performed
using apoB- and b-actin- specific antibodies. As shown
in Figure 2B, the expression level of apoB in HepG2
cells was much higher than that in HepG2.2.15 cells,
indicating that the apoB protein levels in HepG2 and
HepG2.2.15 cells closely follow the changes in mRNA
levels. In addition, b-actin protein synthesis remained
constant between the two cell lines.
To rule out the possibility that the chosen of
HepG2.2.15 cells coincidentally reduce apoB gene
expression due to the clonal differences between HepG2
and HepG2.2.15 cells, the relative expression of apoB
was reexamined in HepG2 cells transfected with a plas-
mid containing 1.3-fold HBV genome (pHBV1.3) and in
HepG2 cells transfected with a control plasmid (pBlue-
ks). Results showed that both apoB mRNA and protein
levels were significantly reduced in the HBV transfected
HepG2 cells, confiming the specific inhibitory effect on
apoB synthesis in the presence of HBV (Figure 3).
Effect of HBV on levels of MTP mRNA and protein
Both MTP and apoB are major regulators of VLDL
assembly and secretion in the liver. MTP has been
shown to physically interact with apoB and play a cha-
perone role for apoB synthesis. To test the possibility
that HBV might affect MTP expression, MTP mRNA
and protein levels in the HBV transfected HepG2 cells
were measured by RT-PCR and Western blot respec-
tively. As shown in Figure 4, HepG2 cells were trans-
fected with different amounts of pHBV1.3. Both MTP
mRNA and protein levels in the HBV transfected
HepG2 cells decreased in a dose-dependent fashion.
Discussion
ApoB is the major structural protein associated with the
triglyceride-rich lipoprotein VLDLs and LDLs. Each
VLDL is composed of one molecule of apoB, multiple
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Figure 1 Serum apoB levels in chronic HBV patients and
healthy controls.* p<0.05 (CHB patients versus healthy controls).
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Figure 2 ApoB mRNA and protein expression in HepG2 cells and HepG2.2.15 cells assessed by RT-PCR and Western blot, respectively.
(A) RT-PCR analysis was used to compare the relative levels of apoB mRNA in HepG2 cells and HepG2.2.15 cells. b-actin gene was amplified as
an internal control. PCR products were detected on 2% agarose gel electrophoresis with ethidium bromide stain.(B) Western blot analysis of
apoB protein expression in HepG2 cells and HepG2.2.15 cells. Protein samples from whole cell extracts were fractionated on 12% SDS-PAGE and
then subjected to Western blot using a specific antibody to apoB. b-actin was the internal control.
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amounts of lipids (mainly triglycerides). Since the liver
plays a fundamental role in lipid metabolism, alterations
of liver function are correlated with modifications of cir-
culating lipids [14,15]. Viral hepatitis is a common cause
of hepatic dysfunction and increased reports have
demonstrated evident changes in serum lipid,
lipoprotein, and apolipoprotein patterns in patients
infected with either HBV or HCV [16-18]. In this study,
we first measured and compared serum apoB levels in a
series of patients with HBsAg positive chronic HBV
infection and in healthy individuals. Results showed that
the serum apoB levels were significantly lower in
chronic HBsAg carriers than in normal controls. The
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Figure 3 ApoB mRNA and protein expression in HepG2 cells transfected with pHBV1.3 and HepG2 cells transfected with pBlue-ks
assessed by RT-PCR and Western blot, respectively. (A) RT-PCR analysis was used to compare the relative levels of apoB mRNA in HepG2
cells transfected with pHBV1.3 and HepG2 cells transfected with pBlue-ks. b-actin gene was amplified as an internal control. PCR products were
detected on 2% agarose gel electrophoresis with ethidium bromide stain.(B) Western blot analysis of apoB protein expression in HepG2 cells
transfected with pHBV1.3 and HepG2 cells transfected with pBlue-ks. Protein samples from whole cell extracts were fractionated on 12% SDS-
PAGE and then subjected to Western blot using a specific antibody to apoB. b-actin was the internal control.
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Figure 4 MTP mRNA and protein expression in HepG2 cells transfected with different amounts of pHBV1.3. (A) RT-PCR analysis was used
to compare the relative levels of MTP mRNA in HepG2 cells transfected with 0 μg, 0.5 μg, 1 μg, and 2 μg pHBV1.3. b-actin gene was amplified
as an internal control. PCR products were detected on 2% agarose gel electrophoresis with ethidium bromide stain.(B) Western blot analysis of
MTP protein expression in HepG2 cells transfected with 0 μg, 0.5 μg, 1 μg, and 2 μg pHBV1.3. Protein samples from whole cell extracts were
fractionated on 12% SDS-PAGE and then subjected to Western blot using a specific antibody to MTP. b-actin was the internal control.
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lipid metabolism are not well understood. To extend
our knowledge in this area, we then evaluated the effects
of HBV on apoB mRNA and protein levels at the cellu-
lar level. We chose HepG2 cell line as an in vitro model
for investigating the influence of HBV on apoB expres-
sion because HepG2 cell has long been used for study-
ing HBV biology and HBV host-pathogen interaction
and the cell line can mimic the in vivo synthesis of apo-
lipoproteins. Results from our cell study confirmed that
the reduction of apoB synthesis is associated with the
effects of hepatitis B virus itself rather than other
responses.
All these information raised questions on the precise
role of possible key virological factors that affect apoB
synthesis. Unfortunately, due to the lack of close to rea-
lity cell-culture system and animal model, it is hard for
us to specify the details of the mechanism by which
HBV infection alters apoB expression. However, we can
get informative cues by the comparison of HBV and
HCV as the relationships between HCV infection and
lipid metabolism have been under intensive investiga-
tion [19-21]. Although their genome structure and
molecular organization are different, HBV and HCV uti-
lize some common strategies to invade and replicate in
hepatocytes. Among them, both viruses share common
routes of transmission, depend on host cell machinery
to carry out viral gene expression, and are able to estab-
lish persistent infection and chronic liver diseases. A
unique property of HCV is its association with lipid
metabolism throughout its life cycle. The multifaceted
interactions between HCV and lipid metabolism facili-
tate the entry and replication of virus in host cell as
well as allow virus to evade immune surveillance. It has
been reported that one of the HCV nonstructural pro-
teins NS5A inhibits apoB secretion [22]. Similar to
NS5A, HBV × protein is a multifuncional transactivator
that has been shown to transactivate a variety of virus
and host cell promoters [23]. Thus, we propose that
HBx might be one of the key molecules in the regula-
tion of apoB synthesis. Our hypothesis of the role of
HBx was verified by the discovery that HBx could
increase the expression of b1,4-N-acetylglucosaminyl-
transferase III (GnT-III), which induced aberrant glyco-
sylation of apoB and disrupted apoB secretion [24]. To
better understand the regulation of apoB gene expres-
sion, the cis-acting elements on the apoB promoter and
the putative transacting factors which interact with
these elements have been defined. Therefore, develop-
ment of tissue culture systems that support replication
of HBV and production of infectious virions is quite
urgent so as to permit a more complete understanding
of the molecular basis of the interactions between HBV
and lipid metabolism.
Our studies further revealed that MTP synthesis was
decreased in HBV transfected HepG2 cells. This result
provides another reasonable explanation to the HBV-
induced apoB reduction. MTP is an intracellular lipid
transfer protein that catalyzes the transport of triglycer-
ide, cholesteryl ester, and phospholipid molecules
between membranes. It is a heterodimer of two proteins
of molecule weight 97 kD and 58 kD, both of which are
required for functional activity. MTP plays an essential
role in the cotranslocational lipidation of apoB as newly
synthesized apoB is translocated into the lumen of the
endoplasmic reticulum (ER), MTP can also binds
directly to the nascent apoB to play a chaperone role in
directing apoB into the ER lumen. Hepatic overexpres-
sion of MTP results in increased in vivo secretion of
VLDL triglycerides and apoB [25,26].
In addition to functioning primarily as an energy
reserve and as building material of the cell membrane of
almost all living organisms, lipids participate in the host
immune response to infections. It appears that triglycer-
ide-rich lipoproteins such as VLDL can inactivate a vari-
ety of infectious agents, play an immune regulatory role,
and are involved in the maintenance of immunologic
homeostasis [27]. Actually, lipid metabolism and
immune response are tightly integrated and the proper
function of each is dependent on the other. The inhibi-
tory effects of HBV on apoB and MTP expression sug-
gest that HBV may interfere with VLDL assembly and/
or secretion, which would represent an unusual virus-
host interaction that favors evasion of the host antiviral
immune response.
In summary, the results of our clinical examination
and cell study demonstrate the ability of HBV to disturb
apoB expression, which may provide practical informa-
tion contributing to the diagnosis of liver pathology and
effective therapies for HBV infection.
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